Cellics Therapeutics

Cellics Therapeutics

  • Founded: 2014
  • Location: San Diego, CA
  • Employee range: 11 - 50
  • Clinical stage: Clin0
  • Therapy area: MRSA pneumonia
  • Drug types: INF, IMM
  • Lead product: CTI-005
  • Product link: https://www.cellics.com/pipeline/
  • Funding: $4M grant Oct 2020



job board

Short description:

Nanosponge Technology

Drug notes:

CTI-111 Clin0 sepsis; undisclosed programs Clin0 autoimmune, inflammatory & infectious diseases, drug delivery

Long description:

Cellics Therapeutics is pioneering drug delivery through cellular nanoparticles (CNPs). A major limitation to any gene therapy approach is the efficient and selective targeting of the genetic cargo to the cell of interest. Cellic’s two nanoplatforms, Cellular Nanosponges and the Cellular Nanoparticle drug delivery technology, harness the power of cell membranes to create CNPs for drug delivery. The cell membranes which can come from wild-type or engineered cells coat the CNPs with their intracellular contents removed. Instead, Cellic’s CNPs can be filled and used to deliver mRNA, siRNA, proteins and small molecules. Using their technology, Cellics is hoping to address serious diseases with high unmet clinical need.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com